Menu
GWAS Study

Genetic Modifiers of Cystic Fibrosis Lung Disease Severity: Whole Genome Analysis of 7,840 Patients.

Zhou YH, Gallins PJ, Pace RG et al.

36921087 PubMed ID
GWAS Study Type
7840 Participants
Scroll to explore
Chapter I

Publication Details

Comprehensive information about this research publication

Authors

ZY
Zhou YH
GP
Gallins PJ
PR
Pace RG
DH
Dang H
AM
Aksit MA
BE
Blue EE
BK
Buckingham KJ
CJ
Collaco JM
FA
Faino AV
GW
Gordon WW
HK
Hetrick KN
LH
Ling H
LW
Liu W
OF
Onchiri FM
PK
Pagel K
PE
Pugh EW
RK
Raraigh KS
RM
Rosenfeld M
SQ
Sun Q
WJ
Wen J
LY
Li Y
CH
Corvol H
SL
Strug LJ
BM
Bamshad MJ
BS
Blackman SM
CG
Cutting GR
GR
Gibson RL
OW
O'Neal WK
WF
Wright FA
KM
Knowles MR
Chapter II

Abstract

Summary of the research findings

Rationale: Lung disease is the major cause of morbidity and mortality in persons with cystic fibrosis (pwCF). Variability in CF lung disease has substantial non-CFTR (CF transmembrane conductance regulator) genetic influence. Identification of genetic modifiers has prognostic and therapeutic importance. Objectives: Identify genetic modifier loci and genes/pathways associated with pulmonary disease severity. Methods: Whole-genome sequencing data on 4,248 unique pwCF with pancreatic insufficiency and lung function measures were combined with imputed genotypes from an additional 3,592 patients with pancreatic insufficiency from the United States, Canada, and France. This report describes association of approximately 15.9 million SNPs using the quantitative Kulich normal residual mortality-adjusted (KNoRMA) lung disease phenotype in 7,840 pwCF using premodulator lung function data. Measurements and Main Results: Testing included common and rare SNPs, transcriptome-wide association, gene-level, and pathway analyses. Pathway analyses identified novel associations with genes that have key roles in organ development, and we hypothesize that these genes may relate to dysanapsis and/or variability in lung repair. Results confirmed and extended previous genome-wide association study findings. These whole-genome sequencing data provide finely mapped genetic information to support mechanistic studies. No novel primary associations with common single variants or rare variants were found. Multilocus effects at chr5p13 (SLC9A3/CEP72) and chr11p13 (EHF/APIP) were identified. Variant effect size estimates at associated loci were consistently ordered across the cohorts, indicating possible age or birth cohort effects. Conclusions: This premodulator genomic, transcriptomic, and pathway association study of 7,840 pwCF will facilitate mechanistic and postmodulator genetic studies and the development of novel therapeutics for CF lung disease.

7,437 European ancestry individuals, 403 individuals

Chapter III

Study Statistics

Key metrics and study information

7840
Total Participants
GWAS
Study Type
No
Replicated
European
Ancestry
Canada, U.S., France
Recruitment Country
Chapter IV

Analysis

Comprehensive review of health and genetic findings

Important Disclaimer: This review has been performed semi-automatically and is provided for informational purposes only. While we strive for accuracy, this analysis may contain errors, omissions, or misinterpretations of the original research. DNA Genics disclaims all liability for any inaccuracies, errors, or consequences arising from the use of this information. Users should independently verify all information and consult original research publications before making any decisions based on this content. This analysis is not intended as a substitute for professional scientific review or medical advice.

Analysis In Progress

Our analysis of this publication is currently being prepared. Please check back soon for comprehensive insights into the health and genetic findings discussed in this research.